Twenty-two UK life sciences companies and a further 10 academic groups will share £39 million (US$62.3 million) in research funding in the largest grant allocation that the Biomedical Catalyst scheme has made to date.
A recent decision by the Irish government to abolish the independent office of the Chief Scientific Adviser and to amalgamate the role with that of the director general (DG) of Science Foundation Ireland (SFI) has elicited a curious mix of protest and silence.
French diagnostics firm Skuldtech SAS has emerged as the company behind a phenotypic biomarker that offers a simple predictive indication of which pancreatic cancer patients will benefit from an investigational tyrosine kinase inhibitor (TKI) currently under regulatory review in Europe.
Twenty-two UK life sciences companies and a further 10 academic groups will share £39 million (US$62.3 million) in research funding in the largest grant allocation that the Biomedical Catalyst scheme has made to date.
Aided by a generous dollop of government cash, a French consortium of biotechnology companies and academic medical centers is investing €80 million (US$104 million) to develop an industrial-scale facility for the production of cell therapy, including stem cell therapy.
Covagen AG signed its first drug discovery deal last week, a pact worth potentially up to €112.25 million (US$146 million) with Mitsubishi Tanabe Pharma Corp. that involves its Fynomer protein scaffold technology.
The management of Dutch drug delivery specialist OctoPlus NV agreed to a €27.4 million (US$35.8 million) cash offer from Indian generics firm Dr. Reddy's Laboratories Ltd.
In an eagerly awaited milestone for the company – and for Belgian biotech – the FDA recently approved ThromboGenics NV's biologic drug Jetrea (ocriplasmin) for treating symptomatic vitreomacular adhesion (VMA).
Aided by a generous dollop of government cash, a French consortium of biotechnology companies and academic medical centers is investing €80 million (US$104 million) to develop an industrial-scale facility for the production of cell therapy, including stem cell therapy.
The management of Dutch drug delivery specialist OctoPlus NV agreed to a €27.4 million (US$35.8 million) cash offer from Indian generics firm Dr. Reddy's Laboratories Ltd.
